Ground-breaking microbiome data platform Eagle Genomics has announced a partnership with Microsoft Genomics.
The e[automateddatascientist] platform can be employed to assess a product’s suitability for retail / consumption by assessing its impact on the microbiome. The technology is already employed by a number of global companies, including Unilever and GSK. This collaboration will enable the solution to be scaled at the enterprise level.
“We are delighted to partner with Microsoft Healthcare on its Genomics service and look forward to working together to unlock the potential of the microbiome and solve some of the grand challenges of our age,” Anthony Finbow, CEO of Eagle Genomics commented. “We are seeing strong demand for our knowledge discovery platform amongst enterprise customers in the biotech and pharma, food and personal care industries as they embrace the digital reinvention of Life Sciences R&D. Microsoft Genomics will help tackle the computing and scaling challenges, accelerating the adoption of the technologies and the launch of new products and therapies, heralding a new era in scientific discovery.”
Geralyn Miller, Director of Microsoft Genomics added, “This collaboration with Eagle Genomics presents exciting opportunities to gain meaningful insight from microbiome data, an area of research that, when better understood, promises to have a significant impact on our health and wellbeing. This is in line with Microsoft’s mission to bring the power and scale of the cloud to precision-medicine, spanning the productization of core services and fundamental research.”
Want to know more about the microbiome trend from a personal care perspective? We explored the burgeoning category with three experts in the field in a dedicated podcast, which you can find here.